Serum electrolytes showed serum creatinine 0.8 mg/dL, blood urea nitrogen (BUN) 31 mg/dL, bicarbonate 15.8 mmol/L, serum glutamic pyruvic transaminase 2 695 IU/L, serum glutamic oxaloacetic transaminase
7 559 IU/L and serum creatine phosphokinase 1 967 IU/L.
The serum glutamic oxaloacetic transaminase
(GOT) and glutamic pyruvic transaminase (GPT) were measured by the IFCC method (Hitachi 917[R] device, Roche Diagnostics, Florida, USA).
Fasting blood glucose (FBG), glycated hemoglobin (HbAlc), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), serum glutamic oxaloacetic transaminase
(SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatase (ALP), blood urea nitrogen (BUN) and creatinine levels were measured at baseline and after 2 months study treatment.
The results of liver function tests were as follows: total bilirubin level 268 [micro]mol/l (direct 166 [micro]mol/l), serum glutamic oxaloacetic transaminase
32 IU/l, serum glutamic pyruvate transaminase 40 IU/l, serum alkaline phosphatase 1 270 IU/l and gamma-glutamyl transpeptidase 760 IU/l.
Serum glutamic oxaloacetic transaminase
(SGOT) is an enzyme, majorly present in the heart muscle, liver tissues, skeletal muscles, and kidneys.
Arterial blood samples (0.5 mL) were collected for measurement of glutamic oxaloacetic transaminase
(GOT), glutamic pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine (Cre), lactic dehydrogenase (LDH), creatine phosphokinase (CPK), and ethanol at 3h before induction of HS, and at 0, 1, 3, 6, 9, 12, 18, 24, and 48 h following HS, while an equal volume of 0.5 mL normal saline was used for fluid resuscitation.
Two-thirds of the patients had an ST-elevation MI; the rest had symptoms compatible with an AMI with electrocardiographic changes accompanied by an increase in serum glutamic oxaloacetic transaminase
or creatine phosphokinase.
Effects on various biochemical components such as some enzymes e.g., acid phosphatase (AcP), alkaline phosphatase (AkP), amylase, cholinesterase (ChE), glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase
(GOT), and trehalase and among metabolites free amino acids (FAA), glucose, glycogen, soluble protein, total protein, total lipids, trehalose, DNA and RNA contents were studied.
Abbreviations SGOT Serum glutamic oxaloacetic transaminase
; SGPT Serum glutamic pyruvic transaminase; ALP Alkaline phospatase; HEHE Hydroethanolic extract of Hybanthus enneaspermus
The relation between HCV genotypes and serum glutamic pyruvic transaminase (SGPT), serum glutamic oxaloacetic transaminase
(SGOT), total protein, total bilrubin, and alkaline phosphatase was studied.
The primary endpoints of the study were improvement in signs and symptoms of hepatic disorders such as anorexia, abdominal discomfort, flatulence, lethargy, nausea, hepatomegaly and jaundice, and improvement in the biochemical parameters, viz serum protein, serum bilirubin, serum glutamic oxaloacetic transaminase
(SGOT) (replaced in Australia with aspartate aminotransferase--AST), serum glutamic pyruvic transaminase (SGPT) (replaced in Australia with alanine aminotransferase--ALT), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (GGT).
Exclusion criteria included renal insufficiency (creatinine >1.5 mg/dl), liver dysfunction (glutamic oxaloacetic transaminase
>40 U/l, glutamic pyruvic transaminase >40 U/l), symptomatic ischaemic or valvular heart disease, anaemia (haemoglobin <90 g/l) and symptomatic pulmonary dysfunction (or a ratio of forced expiratory volume in one second to the forced vital capacity (FEV1/FVC) <65%.
Further a significant fall in the blood sugar level (t =4.389, d.f.=3, P<0.05) was noted in the treated mice as compared to the control one, while there was significant rise in the level of liver enzymes, Serum Glutamic Oxaloacetic Transaminase
(SGOT) (t =12.247, d.f.=3, P<0.01) and Serum Glutamic Pyruvic Transaminase (SGPT) (t =4.074, d.f.=3, P<0.05) in the treated mice (Table 3).
We also measured serum hepatic enzymes, including glutamic pyruvic transaminase, glutamic oxaloacetic transaminase
, and total lactic dehydrogenase, in all patients in each treatment group at days 0 and 28 (CL 1000 biochemical analyzer).
Serum albumin was 28 g/L (normal 33-48 g/L), serum glutamic oxaloacetic transaminase
54 U/L (normal 5-40 U/L), serum glutamic pyruvate transaminase 58 U/L (normal 5-40 U/L), and erythrocyte sedimentation rate 74 mm/h.